Implications for the Clinical Neurologist," Dr. Alcolea et al. 1 reviewed the medical literature and summarized a large and rapidly expanding area of research: the use of biomarkers in neurodegenerative diseases.These illnesses tend to progress very slowly over time and cause problems with thinking, memory, movement, language, and judgment.In the past few years, there have been great advances in the ability to consistently and accurately detect the abnormal proteins in the blood that occur in certain neurologic illnesses such as Alzheimer disease.These abnormal proteins are known as biomarkers.Biomarkers are measurable substances that signal the presence of an illness.Biomarkers can be found with many kinds of tests.For instance, an MRI can measure changes in the brain that occur because of Alzheimer disease.These measurable changes, visible in the pictures of the brain taken during an MRI, are one kind of biomarkers.In another type of test, specialized radioactive (do not worry, it is safe) molecules are injected into the bloodstream.This highlights areas where a disease is most active.A measure of that activity is another form of biomarker.Some of these tests are easy to perform and to repeat, such as blood testing.Other tests such as a lumbar puncture (also called a spinal tap) are more difficult to perform and often need to be performed by a specialist.Recent research in Alzheimer disease has focused on testing for the presence of biomarkers in the blood.The reasons for this are simple: blood samples are relatively easy to collect, are minimally invasive, and can easily be used to follow-up an illness over time.Although it may seem simple, measuring a biomarker of a brain disease can be difficult.This is because the brain is isolated from the blood by a structure called the blood-brain barrier (BBB).There are very few substances that can cross the BBB.This means that very